Chronic Lymphocytic Leukemia

The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin has been granted breakthrough therapy designation by the FDA as a potential treatment for relapsed or refractory acute lymphoblastic leukemia patients.

John C. Byrd, MD, on Hematologic Malignancies in Chicago about novel agents in treating chronic lymphocytic leukemia, specifically about the emergence of new targeted therapies, including ibrutinib (Imbruvica) and idelalisib (Zydelig) and what clinicians should know about them.

Relapsed and Refractory CLL with Javier Pinilla-lbarz, MD, PhD and Paul Barr, MD

Relapsed and Refractory CLL with Javier Pinilla-lbarz, MD, PhD and Paul Barr, MD

Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute, discusses new drugs on the horizon for the treatment of patients with chronic lymphocytic leukemia (CLL).

A new study suggests that the presence of persistent genetic mutations, 30 days after induction chemotherapy, predicted relapse and survival in patients with acute myeloid leukemia (AML), as well as intermediate-risk patients.